Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...

With the possibility of Robert F. Kennedy, Jr. being involved in health policy in the next administration, vaccination – ...

There is no evidence Japan has named the COVID-19 vaccine the “most deadly drug in history,” as the post claims.

They found that mRNA vaccines that target C. diff cells and the toxins they produce generated a lasting immune response in ...

With a market cap of $18 billion, Moderna is at the forefront of innovative healthcare solutions, pioneering treatments for ...

The study demonstrates that activating the vitamin D receptor (VDR) with calcitriol suppresses cell proliferation in ...

Reactogenicity is comparable for simultaneous and sequential administration of mRNA COVID-19 and influenza vaccines.

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other most promising gene ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...

The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...

The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products ...